Urinary Tract Cancer Market Report 2026

Urinary Tract Cancer Market Overview

• Urinary Tract Cancer market size has reached to $3.84 billion in 2025 • Expected to grow to $9.29 billion in 2030 at a compound annual growth rate (CAGR) of 19.5% • Growth Driver: Rising Bladder Cancer Cases Fuel Expansion Of The Urinary Tract Cancer Market • Market Trend: Next-Generation Therapies Show Promise In Improving Outcomes For Muscle-Invasive Bladder Cancer • North America was the largest region in 2025.

What Is Covered Under Urinary Tract Cancer Market?

Urinary tract cancer refers to malignancies that develop in the kidneys, bladder, ureters, or urethra, often causing symptoms like blood in the urine and pain. The preventive steps such as stopping smoking, avoiding hazardous substances and promptly treating urine infections may help minimize the risk of getting urinary tract cancer. The main types of urinary tract cancer are bladder cancer, urethral cancer, ureteric cancer and renal pelvic cancer. Bladder cancer refers to the abnormal growth of cells within the bladder lining that directly affects the urinary tract since the bladder is a crucial component of the urinary system and It is treated with radical cystectomy, radiation therapy and targeted therapy. They are also treated with chemotherapy, intravenous therapy, radiation therapy and surgery and diagnosed with cystoscopy, transurethral resection of the tumor, imaging tests, urine analyses and other techniques. The treatment and diagnostic products are distributed through channels such as retail pharmacies and online pharmacies.

What Is The Urinary Tract Cancer Market Growth Forecast?

The urinary tract cancer market size is expected to see rapid growth in the next few years. It will grow to $9.29 billion in 2030 at a compound annual growth rate (CAGR) of 19.5%. The growth in the forecast period can be attributed to increasing investments in personalized oncology treatments, rising adoption of immunotherapy approaches, expansion of AI-assisted diagnostic tools, growing focus on early screening programs, advancements in minimally invasive cancer surgery. Major trends in the forecast period include increasing adoption of targeted cancer therapies, rising use of advanced diagnostic imaging techniques, growing integration of precision oncology approaches, expansion of multimodal treatment strategies, enhanced focus on early cancer detection.

What Is The Driver Of The Urinary Tract Cancer Market?

The growing prevalence of bladder cancer is expected to propel the growth of the urinary tract cancer market. Bladder cancer refers to the development of cancerous cells within the tissues of the urinary bladder, which is a hollow organ in the pelvis responsible for storing urine produced by the kidneys until it is excreted from the body. This higher prevalence leads to greater demand for diagnostic tools, screening methods and treatment options for urinary tract cancer patients. For instance, in January 2023, according to the report published by the American Cancer Society Inc., a US-based voluntary organization for cancer awareness, the estimated cases of urinary system cancer increased to 168,560 in 2023, an increase of 2.66% from 164,190 in 2022 in the United States. Therefore, the growing prevalence of bladder cancer will drive the growth of the urinary tract cancer industry.

Key Players In The Global Urinary Tract Cancer Market

Major companies operating in the urinary tract cancer market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck KGaA, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC (GSK), Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Eisai Co. Ltd., Boehringer Ingelheim GmbH, Incyte Corporation, Seagen Inc., Exelixis Inc., UroGen Pharma Inc., Mersana Therapeutics, Spectrum Pharmaceuticals

Global Urinary Tract Cancer Market Trends and Insights

Major companies operating in the urinary tract cancer market are focusing on launching next-generation therapies, such as antibody-drug conjugate (ADC) and immune-checkpoint inhibitor combination treatments, to deliver more effective and tailored outcomes in urothelial carcinoma. Antibody-drug conjugate immune-checkpoint inhibitor combination treatments refer to novel therapeutic regimens that combine targeted cytotoxic ADCs with checkpoint inhibitors to both kill tumor cells and enhance immune system activation, thereby improving response rates and survival in urinary tract cancers. For instance, in November 2025, Astellas Pharma Inc., a Japan-based healthcare and pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for PADCEV (enfortumab vedotin-ejfv) + KEYTRUDA (pembrolizumab) for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer, featuring a Nectin-4-directed ADC component combined with PD-1 immune-checkpoint blockade, a design aimed at reducing recurrence, progression, or death by ~60% versus surgery alone, and a regulatory path with a target action date of April 7, 2026, under the FDA’s Priority Review program.

What Are Latest Mergers And Acquisitions In The Urinary Tract Cancer Market?

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for an $43 billion. Through this acquisition, Pfizer aims to enhance its oncology portfolio by integrating Seagen’s antibody-drug conjugate (ADC) technology and approved medicines to accelerate cancer treatment innovation. Seagen Inc. is a US-based biotechnology company that provides treatments for urinary tract cancer, specifically urothelial cancer, which is the most common type of bladder cancer

What Defines the Urinary Tract Cancer Market?

The urinary tract cancer market consists of revenues earned by entities by providing services such as diagnostic services, surgery and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinary tract cancer market also includes sales of urinary catheters, cystoscopes, imaging equipment, urine cytology kits, pain relief medications and physical therapy devices which are used in providing diagnostic services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Urinary Tract Cancer Market Report 2026?

The urinary tract cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the urinary tract cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.